GLP-1R Agonist Treatment for Opioid Use Disorder

What this study is testing ClinicalTrials.gov NCT06548490 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study

Treatments tested

• Semaglutide Pen Injector also known as Ozempic Drug

  Semaglutide will be provided using an injection pen

• Placebo also known as Dry needle stick Drug

  Placebo will be a dry needle stick; no substances will be injected